Recent developments highlight growth in insurance policy volumes and premiums through RELI Exchange, capital raising activities, strategic investments in technology and life sciences, and debt reduction efforts.

• Reliance Global Group reported a 72% increase in health insurance policies written through RELI Exchange during 2025 open enrollment [N2].
• The company announced a 36% year-over-year increase in personal lines property and casualty written premium through RELI Exchange [N3].
• Reliance Global Group priced a $2 million public offering in January 2026 [N5].
• The company plans a majority stake acquisition in AI breath diagnostics firm Scentech [N6].
• Reliance Global Group reduced long-term debt by approximately 50% to enhance financial flexibility as of July 2025 [N7].
• The company reported strong preliminary Q1 2025 financial results for Spetner Associates, Inc. amid acquisition progress [N8].
• Reliance Global Group launched RELI Auto Leasing to enhance revenue opportunities for agency partners [N1].
• The company is executing a transformative OneFirm strategy as of early 2026 [N1].

The company’s insurance platform, RELI Exchange, has shown strong growth in health insurance policies and personal lines premiums, indicating operational momentum. The reduction of long-term debt and successful capital raises enhance financial flexibility. Strategic investments in emerging technology and life sciences sectors, including AI diagnostics and post-quantum cryptography, could diversify revenue streams and position the company in high-growth markets. The OneFirm strategy and new operating models like Scale51 reflect management’s intent to build a multi-sector platform.

The company faces significant risks related to Nasdaq listing compliance, including minimum market value and bid price requirements, which could lead to delisting and reduced liquidity. Expansion into technology and life sciences sectors involves early-stage, speculative investments with high capital needs and operational challenges. Limited management experience in these sectors and potential conflicts of interest from related party transactions may impair execution. The company reported a net loss and negative earnings per share, reflecting ongoing operational and investment costs. Market acceptance and regulatory approvals for new technologies and life sciences products remain uncertain.

Reliance Global Group’s moat is anchored in its established insurance brokerage and InsurTech platform, RELI Exchange, which has demonstrated growth in written premiums and policy volumes. The company’s expansion into technology and life sciences sectors is nascent and involves early-stage investments with uncertain competitive advantages. The company’s ability to leverage its existing insurance platform and cross-sell new products may provide some strategic advantage, but the moat in new sectors is currently limited due to lack of operating history and competitive positioning.

• Nasdaq Listing Compliance Risk: The company has recently faced non-compliance with Nasdaq’s minimum bid price and market value of listed securities requirements, with potential risk of delisting that could adversely affect liquidity and access to capital markets [S2].
• Early-Stage Investment Risk: Investments in technology (e.g., Enquantum) and life sciences (e.g., Innervate) are highly speculative, with risks including product development failure, regulatory hurdles, capital needs, and market acceptance [S2].
• Limited Operating Experience in New Sectors: Management has limited direct experience operating technology and life sciences businesses, which may impair the company’s ability to identify, evaluate, and manage investments effectively [S2].
• Capital and Funding Risk: Ongoing capital commitments to early-stage investments may exceed current expectations, and external financing may not be available on acceptable terms, potentially impairing investment value and company liquidity [S2].
• Related Party and Conflict of Interest Risk: The life sciences platform LGG involves related party ownership and management roles, creating potential conflicts of interest that may affect decision-making and shareholder value [S2].
• Intellectual Property and Regulatory Risks: Technology investments depend on securing and defending intellectual property rights and navigating complex regulatory environments, with risks of infringement claims and failure to obtain approvals [S2].
• Geopolitical and Cross-Border Risks: Investments in Israeli-based companies expose the company to geopolitical, legal, and regulatory risks that could adversely affect operations and investment value [S2].

• Reliance Global Group, Inc. is a publicly traded company on the Nasdaq Capital Market under the ticker EZRA [S1].
• The company operates insurance brokerage and InsurTech businesses, with recent expansion into technology and life sciences sectors through subsidiaries EZRA International Group LLC and LifeSci Global Group LLC [S2].
• The company reported $2,110,815 in revenue and a net loss of $1,991,371 for the quarter ended June 30, 2026, with basic and diluted EPS of -3.26 USD per share [S2].
• Liquidity ratios as of June 30, 2026, include a current ratio of 1.63 and a cash ratio of 5.17, with cash and equivalents of $10,018,000 and current liabilities of $1,935,864 [S2].
• Reliance Global Group has a platform called RELI Exchange, through which it reported a 72% increase in health insurance policies written during 2025 open enrollment and a 36% year-over-year increase in personal lines property and casualty written premium [N2][N3].
• The company announced a $2 million public offering priced in January 2026 [N5].
• Reliance Global plans a majority stake acquisition in AI breath diagnostics firm Scentech [N6].
• The company reduced long-term debt by approximately 50% to enhance financial flexibility as of July 2025 [N7].
• Reliance Global Group has reported strong preliminary Q1 2025 financial results for Spetner Associates, Inc. amid acquisition progress [N8].
• The company has launched RELI Auto Leasing to enhance revenue opportunities for agency partners [N1].
• The company has a transformative OneFirm strategy as of early 2026 [N1].
• The company faces Nasdaq listing risks including minimum Market Value of Listed Securities and minimum bid price requirements, with recent compliance regained on the minimum bid price rule but potential risk of future non-compliance [S2].
• The technology sector expansion involves early-stage investments such as Enquantum, a post-quantum cryptography company, which is early-stage, revenue-negative, and dependent on milestone funding from Reliance Global [S2].
• The life sciences sector expansion is through LifeSci Global Group LLC (LGG), a newly formed entity with no operating history, with initial investment in Innervate, an early-stage radiopharmaceutical company [S2].
• The company’s investments in technology and life sciences sectors involve significant risks including limited operating experience, capital requirements, regulatory and intellectual property risks, and potential conflicts of interest due to related party transactions [S2].